EXPERIMENTAL HEMATOLOGY

Scope & Guideline

Exploring Innovations in Hematology and Beyond

Introduction

Welcome to the EXPERIMENTAL HEMATOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of EXPERIMENTAL HEMATOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0301-472x
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1973 to 2024
AbbreviationEXP HEMATOL / Exp. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

EXPERIMENTAL HEMATOLOGY focuses on advancing the understanding of hematopoiesis, hematological malignancies, and related therapeutic interventions. The journal emphasizes innovative research methodologies and interdisciplinary approaches to address key challenges in the field.
  1. Hematopoiesis and Stem Cell Biology:
    The journal covers extensive research on the mechanisms of hematopoiesis, including the development, differentiation, and function of hematopoietic stem cells (HSCs), progenitor cells, and their niches.
  2. Hematological Malignancies:
    Research on the molecular and cellular basis of hematological cancers, including leukemias, lymphomas, and myeloproliferative neoplasms, is a core area of focus, particularly mechanisms of tumorigenesis and therapeutic resistance.
  3. Therapeutic Innovations:
    EXPERIMENTAL HEMATOLOGY publishes studies on novel therapeutic strategies, including gene therapy, immunotherapy, and targeted treatments for hematological diseases, highlighting translational research.
  4. Microenvironment and Niche Interactions:
    The journal emphasizes the role of the bone marrow microenvironment and other niches in regulating hematopoietic cell behavior, interactions between different cell types, and their impact on disease.
  5. Epigenetics and Transcriptional Regulation:
    Research exploring the epigenetic landscape and transcriptional control mechanisms governing hematopoietic development and malignancies is prominently featured, reflecting the journal's commitment to understanding gene regulation.
  6. Systemic and Local Regulation of Hematopoiesis:
    Studies addressing the systemic factors influencing hematopoiesis and the local signals from the microenvironment that modulate hematopoietic function are integral to the journal's scope.
EXPERIMENTAL HEMATOLOGY is currently witnessing several emerging themes that reflect the cutting-edge advancements in hematology research. These trends indicate a shift towards more innovative methodologies and interdisciplinary approaches.
  1. Single-Cell Technologies:
    An increasing number of studies are employing single-cell RNA sequencing and other single-cell technologies to elucidate the heterogeneity of hematopoietic stem and progenitor cells, providing insights into their function and regulation.
  2. Metabolic Regulation:
    Research focusing on the metabolic pathways that influence hematopoietic stem cell function and differentiation is gaining prominence, highlighting the interplay between metabolism and cell fate.
  3. Inflammation and Immune Interactions:
    The role of inflammation and immune responses in regulating hematopoiesis and hematological malignancies is an emerging theme, with studies investigating how these factors influence disease progression.
  4. Gene Editing and Genetic Models:
    There is a notable increase in studies utilizing advanced gene editing techniques (e.g., CRISPR/Cas9) to model hematological diseases and explore genetic factors contributing to malignancies.
  5. Epitranscriptomics:
    The exploration of RNA modifications (e.g., m6A methylation) and their impact on gene expression and hematopoietic function is an emerging area of interest, reflecting the evolving understanding of post-transcriptional regulation.
  6. Therapeutic Targeting of the Microenvironment:
    Research targeting the bone marrow microenvironment to enhance hematopoietic stem cell recovery and improve treatment outcomes in hematological malignancies is gaining traction, indicating a shift towards niche-focused therapies.

Declining or Waning

While EXPERIMENTAL HEMATOLOGY continues to thrive in many areas, certain themes appear to be waning or experiencing decreased publication frequency. This could reflect shifts in research focus or advances in understanding that render some topics less prominent.
  1. Traditional Animal Models:
    Research utilizing conventional animal models for hematopoiesis and leukemia studies is less frequently published, potentially due to the increasing adoption of advanced in vitro and humanized models.
  2. Basic Hematology without Translational Focus:
    Papers focusing solely on basic hematological research without clear translational implications are becoming less common, as the field increasingly emphasizes studies that bridge basic science with clinical application.
  3. Single-Agent Therapeutic Studies:
    The publication of studies focusing exclusively on single-agent therapies without exploring combination strategies or innovative approaches appears to be declining, reflecting a shift towards more complex treatment paradigms.
  4. Epidemiological Studies:
    There has been a noticeable decrease in the publication of epidemiological studies related to hematological disorders, possibly due to a growing emphasis on mechanistic and experimental research.

Similar Journals

Blood Cancer Discovery

Driving Collaborative Efforts for Better Patient Outcomes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Molecular Oncology

Unlocking Innovations in Molecular Medicine.
Publisher: WILEYISSN: 1574-7891Frequency: 10 issues/year

Molecular Oncology, published by WILEY, is a premier open-access journal that has been at the forefront of cancer research since its inception in 2007. With an impressive impact factor reflective of its outstanding contribution to the field, it holds a prestigious position in the Q1 category across multiple disciplines, including Cancer Research, Genetics, and Molecular Medicine. This journal is essential for researchers and professionals seeking to publish high-quality findings in a rapidly evolving area of study, underscored by its significant Scopus rankings that place it within the top percentiles of Oncology and Molecular Biology. As an open-access journal since 2017, it ensures that vital research is readily available to a global audience, thereby facilitating collaboration and knowledge dissemination among academic and clinical communities. With its commitment to innovative and impactful research, Molecular Oncology continues to be a critical resource for advancing our understanding of cancer biology and treatment.

EXPERIMENTAL CELL RESEARCH

Unveiling Innovations in Experimental Research
Publisher: ELSEVIER INCISSN: 0014-4827Frequency: 20 issues/year

EXPERIMENTAL CELL RESEARCH is a highly respected journal published by Elsevier Inc, specializing in the dynamic and ever-evolving field of Cell Biology. With an impact factor positioned in the Q2 quartile for 2023, it ranks at the 124th position out of 285 in the Scopus Ranks, indicating a solid reputation among peers in the domains of biochemistry, genetics, and molecular biology. Since its inception in 1950, the journal has contributed significantly to the dissemination of groundbreaking research, providing a platform for studies that explore the nuances of cellular mechanisms, processes, and experimental methodologies. Although the journal currently does not offer open access, its commitment to high-quality, peer-reviewed research continues to attract submissions from leading scientists and scholars across the globe. Researchers, professionals, and students alike will find this journal an invaluable resource for keeping abreast of current developments and innovative breakthroughs in cellular science.

BIOCELL

Advancing the Frontiers of Cell Biology
Publisher: TECH SCIENCE PRESSISSN: 0327-9545Frequency: 12 issues/year

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Exploring the molecular mechanisms of life.
Publisher: ELSEVIERISSN: 0167-4889Frequency: 12 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH is a premier journal published by Elsevier, dedicated to advancing the fields of cell biology and molecular biology. Established in 1982, this influential journal has been at the forefront of scientific research and innovation, currently holding esteemed positions with a Q2 ranking in Cell Biology and a Q1 ranking in Molecular Biology for 2023, reflecting its commitment to high-quality scholarship. With an impressive impact factor, it ranks in the 82nd and 78th percentiles for Molecular Biology and Cell Biology, respectively, amongst its peers. Researchers, professionals, and students will find this journal to be an invaluable resource for exploring the latest discoveries and methodologies in the molecular mechanisms underlying cellular functions. Although it is not an open-access journal, the insights offered in its pages contribute significantly to the scientific community's understanding of cellular and molecular processes, ensuring it remains a vital platform for disseminating cutting-edge research.

HEMATOLOGICAL ONCOLOGY

Advancing the Frontiers of Hematological Research
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Journal of Hematology & Oncology

Fostering Excellence in Hematology and Oncology Scholarship
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Egyptian Journal of Haematology

Advancing Hematology: Insights from Egypt and Beyond
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Blood Science

Transforming Understanding of Blood-Related Health Issues
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

JOURNAL OF GENE MEDICINE

Elevating Standards in Gene Medicine Research
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.